2022 Full Year Guidance and Strategic Outlook
Specialty Products & Technologies
Investing to accelerate long-term growth
Revenue
Core Sales* +11.2%
Adjusted Operating
Profit Margin*
$397.1
$366.5
($m)
Sales
26.4%
22.2%
Adjusted Operating Margin
.
•
N Nobel
Biocare
Ormco
SPARK
CLEAR ALIGNER SYSTEM
Orthodontics
- Solid MSD growth in core Brackets & Wires
- Strong growth in North America and Emerging Markets
- Spark continues to accelerate
Implant-based Tooth Replacements
-
- Strong growth in EU and North America; offset by temporary lockdown
in Shanghai, China
- Accelerating growth in regeneratives and prosthetics
Profitability
- YOY margin decline driven by long-term investments in key growth
initiatives and increase in customer facing activities
- Adjusted operating margin expanded 10 bps sequentially, vs. Q4 2021
Q1 2021 Q1 2022
* Core sales growth and adjusted operating profit margin are non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.
6
EnvistaView entire presentation